Treatment Outcomes of Patients with Ductal Carcinoma In Situ Treated at the Faculty of Medicine, Vajira Hospital
Kanisa Rongsriyam, MD1
Affiliation : 1Department of radiology, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Bangkok, Thailand
Background: Ductal carcinoma in situ (DCIS) denotes the presence of malignant cells confined within the basement membrane, commonly referred to as intraductal carcinoma. The incidence of DCIS has surged owing to advancements in breast cancer screening.
Objective: The present study aims to assess the 5 and 10-year disease-free survival (DFS), overall survival (OS), and prognostic factors among patients diagnosed with DCIS, treated at the Faculty of Medicine Vajira Hospital.
Materials and Methods: A retrospective descriptive analysis was conducted on DCIS patients who underwent treatment at the Faculty of Medicine Vajira Hospital, between 2007 and 2022. DFS and OS were evaluated using the Kaplan-Meier method. The study investigated the association between patient-tumor characteristics with DFS using the log-rank test and Cox proportional hazards models.
Results: The study comprised 72 DCIS patients. Both 5-year OS and 5-year DFS were 100%, with 10-year OS remaining at 100% and 10-year DFS at 91.2%. Only expression of Ki-67 index (HR of 5.52; 95% CI: 3.89 to 9.50) is significantly prognostic factor related to recurrence.
Conclusion: DCIS patients demonstrated excellent long-term survival outcomes. Moreover, there was no significant discrepancy in outcomes between mastectomy and BCS plus whole breast radiation. The expression of the Ki-67 index emerged as a crucial prognostic factor influencing recurrence.
Received 10 April 2024 | Revised 30 April 2024 | Accepted 26 May 2024
Keywords : Ductal carcinoma in situ; DCIS; Surgery; Radiotherapy; Outcomes
